<DOC>
	<DOCNO>NCT00248183</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , multi-center outpatient study , adult GAD . Patients 18-65 year age , diagnosis GAD accord DSM-IV criterion , fulfill inclusion/exclusion criterion , enrol study .</brief_summary>
	<brief_title>A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder ( GAD )</brief_title>
	<detailed_description>This randomize , double-blind , placebo control , multi-center outpatient study , adult GAD . Patients 18-65 year age , diagnosis GAD accord DSM-IV criterion , fulfill inclusion/exclusion criterion , enrol study . This randomized , double-blind , placebo control , multi-center outpatient study , adult GAD . Patients 18-65 year age , diagnosis GAD accord DSM-IV criterion , fulfill inclusion/exclusion criterion , enrol study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Naluzotan</mesh_term>
	<criteria>Be male female , 1865 year age Meet DSMIV diagnostic criterion Generalized Anxiety Disorder ( GAD ) Have total score ≥ 20 HAMA score ≥ 2 Items 1 2 ( anxious mood tension ) HAMA Have 20 % decrease total HAMA score period screen visit randomization visit Have negative serum ( βHCG ) pregnancy test screen negative urine pregnancy test baseline ( woman ) Female subject must meet one follow criterion : ( ) Be surgically sterile ( i.e. , bilateral tubal ligation , hysterectomy , bilateral oophorectomy least six month prior first dose PRX00023 ; appropriate documentation require ) OR ( b ) Agree , sexually active , male partner use two ( 2 ) acceptable barrier form contraception ( e.g. , condom diaphragm ) screen one month final dose study drug Male subject must agree female partner use two ( 2 ) acceptable form contraception ( e.g. , condoms hormonal contraceptive ) screen one month follow final dose study drug Be generally good physical health determine Investigator basis medical history , physical examination , screen laboratory result Have ability communicate investigative site staff manner sufficient carry protocol procedure describe Be able understand procedure provide write informed consent prior admission A history inability tolerate , failure respond , two anxiolytic antidepressant drug give adequate dos duration treatment symptom present current illness Prior intolerance buspirone , gepirone , tandospirone 5HT1A agonist A current past history mania , bipolar disorder , schizophrenia , psychotic disorder A current history ( within six month prior screen ) panic disorder , post traumatic stress disorder , major depression , obsessivecompulsive disorder , social phobia , acute stress disorder , adjustment disorder anxious mood , performance anxiety , somatization disorder , principle psychiatric diagnosis ( DSMIV ) could interfere efficacy assessment A history major life event ( e.g . divorce , death family member ) opinion Investigator likely alter efficacy rating course study Clinically significant abnormality laboratory test ECG ( include QTc value &gt; 450 msec male &gt; 470 msec female ) The presence serious clinically unstable neurologic , cardiovascular , hepatic , renal , endocrinologic , pulmonary , hematologic medical illness psychiatric condition would , opinion Investigator , compromise participation study , confound study result , likely lead need early termination study participation hospitalization course study A history allergic reaction two medication different chemical class Use nonprescription drug psychotropic effect within seven ( 7 ) day prior initiation placebo lead Chronic use analgesic opiate ( e.g. , codeine , hydrocodone , oxycodone ) &gt; 6 month use opiate within two week prior screen Introduction change cognitive behavioral therapy , interpersonal therapy , psychotherapy within three month screen Use St. John 's Wort , kava kava , ephedra , psychoactive herbal medication within last two week screen Known suspect substance abuse dependence , include alcohol , within one year screen A positive urine drug screen ( e.g. , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , methadone , methaqualone , opiates , propoxyphene ) screening . The urine drug screen may repeat discussion patient plausible reason positive test substance abuse A history suicide attempt last two year , current suicide risk judgment Investigator Women breast feeding , lactate within three month prior screen , pregnant , expect become pregnant course study , sexually active use medically acceptable double barrier method birth control . Women rely solely oral contraceptive The use investigational drug within 30 day prior enrollment The concomitant use antidepressant , anxiolytic , psychoactive drug Treatment potent inhibitor CYP3A4 , include ketoconazole , itraconazole , HIV protease inhibitor , clarithromycin , erythromycin , cyclosporine Treatment CYP3A4 inducer carbamazepine , barbiturate , phenytoin , rifampin , oral glucocorticoid Treatment psychoactive drug list table within interval specify enrollment Psychoactive drug Interval ( week ) MAO Inhibitors 4 Fluoxetine 4 Fluvoxamine 2 Citalopram 2 Paroxetine 2 Sertraline 2 Buspirone 4 Buproprion 2 Mirtazepine 2 Nefazodone 2 Venlafaxine 2 Duloxetine 2 Trazodone 2 Benzodiazepines Occasional PRN use : 1 Chronic daily use : 4 Tricyclic Heterocyclic Antidepressants 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>